Fenestrated TREO Stent-Graft for AAA

This trial tests a stent-graft system designed to treat abdominal aneurysms, dangerous bulges in the aorta, the body's main blood vessel. The researchers aim to determine if the Fenestrated TREO Stent-Graft System can safely assist people with a specific aneurysm type near the kidneys. Participants will receive the stent-graft through a less invasive procedure and must visit the hospital for regular follow-ups over five years. This trial may suit individuals diagnosed with a juxtarenal abdominal aneurysm that affects their daily life. As an unphased trial, this study offers the opportunity to contribute to medical advancements and potentially improve participants' quality of life.

The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you have a blood coagulation disorder that cannot be managed before and after the procedure, or if you cannot receive certain blood-thinning treatments during and after the procedure.

Research has shown that the Fenestrated TREO Stent-Graft System is generally safe for treating abdominal aneurysms. One study successfully treated aneurysms in 93.1% of patients after one year, with most experiencing no serious complications. Long-term results indicated that the system remained effective over time, with few long-term health issues reported. These findings suggest that patients tolerate the treatment well, making it a promising option for those with this condition.¹²³⁴⁵

The Fenestrated TREO Stent-Graft System is unique because it is specifically designed to treat juxtarenal Abdominal Aortic Aneurysms (AAA) with precision. Unlike traditional stent-grafts, this system features fenestrations—small openings that allow for better customization to fit the patient’s unique vascular anatomy. This tailored approach helps ensure that blood flow to critical arteries is maintained, reducing the risk of complications. Researchers are excited because this innovation could lead to safer and more effective outcomes for patients with complex AAAs compared to standard options.

Research has shown that the Fenestrated TREO Stent-Graft System, which trial participants will receive, effectively treats abdominal aortic aneurysms (AAAs). Long-term studies have found that this stent-graft performs reliably with few complications over time. Designed for endovascular repair, the system can be placed inside the blood vessel with less invasive surgery. This approach is particularly beneficial for treating juxtarenal AAAs, where the aneurysm is near the kidneys. Overall, evidence supports the system’s effectiveness in safely managing these types of aneurysms.¹²⁵⁶⁷